MET and non-small cell lung carcinoma: A recent study investigating first-line immunotherapy in MET exon 14 skipping mutation NSCLC demonstrated that combination chemo-immunotherapy was associated with prolonged progression-free survival (PFS), an increased objective response rate (ORR), and numerically improved overall survival (OS) compared with chemotherapy alone [16].